Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients

[1] Arnould L(2003)Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer Br J Cancer 88 1587-1591

[2] Denoux Y(2004)Identification and validation of an ERBB2 gene expression signature in breast cancers Oncogene 23 2564-2575

[3] MacGrogan G(2005)Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 123 237-243

[4] Penault-Llorca F(2006)Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry Pathology 38 120-124

[5] Fiche M(1992)Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285-4289

[6] Treilleux I(1960)A coefficient for agreement for nominal scales Educ Psychol Meas 20 37-46

[7] Bertucci F(2005)HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results Clin Breast Cancer 6 253-259

[8] Borie N(2000)Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma Mod Pathol 13 1238-1243

[9] Ginestier C(2009)Systematic review of HER2 breast cancer testing Appl ImmunohistochemMol Morphol 17 1-7

[10] Groulet A(2003)Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer Clin Cancer Res 9 1039-1046

[1] Arnould L(2003)Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer Br J Cancer 88 1587-1591

[2] Denoux Y(2004)Identification and validation of an ERBB2 gene expression signature in breast cancers Oncogene 23 2564-2575

[3] MacGrogan G(2005)Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 123 237-243

[4] Penault-Llorca F(2006)Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry Pathology 38 120-124

[5] Fiche M(1992)Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285-4289

[6] Treilleux I(1960)A coefficient for agreement for nominal scales Educ Psychol Meas 20 37-46

[7] Bertucci F(2005)HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results Clin Breast Cancer 6 253-259

[8] Borie N(2000)Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma Mod Pathol 13 1238-1243

[9] Ginestier C(2009)Systematic review of HER2 breast cancer testing Appl ImmunohistochemMol Morphol 17 1-7

[10] Groulet A(2003)Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer Clin Cancer Res 9 1039-1046